NASDAQ:CRSP • CH0334081137
Past quarterly earnings results for CRISPR THERAPEUTICS AG (CRSP), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -1.37 | -1.17 | -16.65% | -211.36% | 864K | 4.327M | -80.03% | -97.58% |
| Q3 2025 | -1.17 | -1.28 | 8.57% | -15.84% | 889K | 9.082M | -90.21% | 47.67% |
| Q2 2025 | -1.29 | -1.45 | 11.00% | 13.42% | 892K | 6.38M | -86.02% | 72.53% |
| Q1 2025 | -1.58 | -1.28 | -23.86% | -10.49% | 865K | 6.628M | -86.95% | 71.63% |
| Q4 2024 | -0.44 | -1.19 | 63.08% | -140.00% | 35.691M | 8.044M | 343.70% | -82.26% |
| Q3 2024 | -1.01 | -1.45 | 30.41% | 28.37% | 602K | 6.944M | -91.33% | - |
| Q2 2024 | -1.49 | -1.55 | 4.06% | -52.04% | 517K | 3.609M | -85.67% | -99.26% |
| Q1 2024 | -1.43 | -1.36 | -5.19% | -113.43% | 504K | 27.076M | -98.14% | -99.50% |
| Q4 2023 | 1.10 | -0.07 | 1,593.05% | 178.01% | 201.206M | 134.27M | 49.85% | - |
| Q3 2023 | -1.41 | -1.99 | 29.13% | 37.05% | 8.117M | -100.00% | -100.00% | |
| Q2 2023 | -0.98 | -2.16 | 54.63% | 59.17% | 70M | 1.742M | 3,918.37% | 34,900.00% |
| Q1 2023 | -0.67 | -1.74 | 61.43% | 71.12% | 100M | 23.44M | 326.62% | 11,011.11% |
| Q4 2022 | -1.41 | -2.35 | 39.87% | 23.37% | 7.265M | -100.00% | -100.00% | |
| Q3 2022 | -2.24 | -2.34 | 4.11% | -34.13% | 100K | 1.649M | -93.94% | -87.50% |
| Q2 2022 | -2.40 | -2.27 | -5.64% | -125.42% | 200K | 2.105M | -90.50% | -99.98% |
| Q1 2022 | -2.32 | -1.98 | -17.46% | -53.64% | 900K | 2.82M | -68.09% | 80.00% |
| Q4 2021 | -1.84 | -1.80 | -1.98% | -22.67% | 12.9M | 2.318M | 456.51% | 3,125.00% |
| Q3 2021 | -1.67 | -1.79 | 6.77% | -26.52% | 800K | 1.145M | -30.13% | 700.00% |
| Q2 2021 | 9.44 | 3.59 | 162.72% | 826.15% | 900.7M | 429.34M | 109.79% | - |
| Q1 2021 | -1.51 | -1.50 | -0.53% | -31.30% | 500K | 1.159M | -56.86% | 150.00% |
| Q4 2020 | -1.50 | -1.30 | -15.52% | - | 400K | 2.372M | -83.14% | - |
| Q3 2020 | -1.32 | -1.21 | -9.22% | - | 100K | 2.066M | -95.16% | - |
| Q2 2020 | -1.30 | -0.97 | -34.71% | - | 18.488M | -100.00% | - | |
| Q1 2020 | -1.15 | -1.07 | -7.34% | - | 200K | 3.103M | -93.55% | - |
Notes
CRISPR THERAPEUTICS AG (CRSP) last reported earnings on 2/12/2026.
CRISPR THERAPEUTICS AG (CRSP) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, CRISPR THERAPEUTICS AG (CRSP) has beaten EPS estimates in 2 out of 4 releases.